Efficacy and safety of molecular targeted agents combined with docetaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: A Meta-analysis
Cong TIAN,Jiongyi WANG,Meiling WANG,Bin JIANG,Feng LIU
DOI: https://doi.org/10.3781/j.issn.1000-7431.2016.33.1006
2016-01-01
Tumori
Abstract:Objective: To evaluate the efficacy and safety of docetaxel-prednisone chemotherapy in combination with molecular targeted agents (MTAs) for patients with metastatic castration-resistant prostate cancer (mCRPC).Methods: A computer-based online search was performed by using Embase, Cochrane Library, PubMed, CNKI (China National Knowledge Infrastructure), Wanfang database, VIP Chinese Science u0026 Technology Journal Database and Chinese Biomedical Literature Database. According to the inclusion and exclusion criteria, the literatures about MTAs in combination with docetaxel plus prednisone for treatment of mCRPC were selected. After evaluating the quality of the included literature and extracting their data, the Meta-analysis was performed using STATA 12.0 software. In this study, the test group was treated with MTAs combined with docetaxel plus prednisone, while the control group was treated with docetaxel plus prednisone. The primary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), prostate-specific antigen (PSA), grades 3-4 adverse reactions and lethal adverse events.Results: Five randomized controlled trials involving 5 886 patients were included. The Meta-analysis showed that PFS was significantly improved in MTAs combined with docetaxel plus prednisone group as compared with docetaxel plus prednisone group [HR (hazard ratio) = 0.93, 95% confidence interval (CI): 0.87-0.99, P = 0.018], though there were no significant differences in OS (HR = 0.98, 95% CI: 0.91-1.04, P = 0.441), ORR [OR (odds ratio) = 1.317, 95% CI: 0.94-1.84, P = 0.106] and PSA (OR = 1.073, 95% CI: 0.82-1.40, P = 0.604) between the two groups. In terms of adverse reactions, there were higher incidence rates of developing grades 3-4 adverse reactions [RR (relative risk) = 1.187, 95% CI: 0.99-1.42, P = 0.062] and lethal adverse events (RR = 1.298, 95% CI: 1.02-2.22, P = 0.039) in the test group than those in the control group.Conclusion: MTAs combined with docetaxel plus prednisone in the treatment of patients with mCRPC can prolong the PFS time. Meanwhile, MTAs increase the incidence rates of adverse reactions, which should be prevented and symptomatically treated. DOI:10.3781/j.issn.1000-7431.2016.33.1006